The American Journal of Medicine RSS feed: Articles in Press. The American Journal of Medicine - "The Green Journal" - publishes original clinical research of interest to physicians in internal medicine, both in academia and community-based practice. The American Journal of Medicine is the official journal of The Association of Professors of Medicine, a prestigious group comprised of chairs of departments of internal medicine at more than 125 medical schools across the country. Each issue carries useful reviews as well as seminal articles of immediate interest to the practicing physician, including peer-reviewed, original scientific studies that have direct clinical significance, and position papers on health care issues, medical education, and public policy. The journal's ISI factor - the international measure of cited manuscripts and scientific impact - is fourteenth in the world among all general medical journals. The AJM publishes studies performed by multi-center groups in the various disciplines of medicine, including clinical trials and cohort studies from large patient populations, specifically: Phase I, phase II, and phase III studies performed under the auspices of groups such as general clinical research centers, cooperative oncology groups, and the like. Reports of patients with common presentations or diseases, especially studies that delineate the natural history and therapy of important conditions. Reviews oriented to the practicing internist and diagnostic puzzles, complete with images from a variety of specialties. Careful physiological or pharmacological studies that explain normal function or the body's response to disease. Analytic reviews such as meta-analyses and decision analyses that use a formal structure to summarize an important field. http://www.amjmed.com//inpress?rss=yesElsevier Inc.en © 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine0002-93432010-07-22 © 2010 Elsevier Inc. All rights reserved. healthpermissions@elsevier.comhttp://www.amjmed.com/article/PIIS000293431000392X/abstract?rss=yesAbstract: The Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study demonstrated a significant increase in myocardial infarction events with dabigatran compared with warfarin, provoking renewed interest in whether vitamin K antagonists are useful drugs for the prevention of myocardial infarction in high-risk patients with atrial fibrillation. Present analyses examined whether there was an increased risk of myocardial infarction associated with non-warfarin anticoagulants (Stroke Prevention with the ORal direct Thrombin Inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial Fibrillation III and IV, RE-LY, Amadeus) or “anticoagulant equivalents” (Atrial fibrillation Clopidogrel Trial with Irbesartan for the prevention of Vascular Events) in patients with atrial fibrillation who are prescribed anticoagulation for stroke thromboprophylaxis. The overall annual event rate for those receiving warfarin was 0.98% compared with 1.32% for those receiving comparators. Warfarin was associated with a significant reduction in myocardial infarction (relative risk 0.77; 95% confidence interval (CI), 0.63-0.95), an effect largely driven by the RE-LY trial. Sensitivity analyses, excluding RE-LY, revealed a nonsignificant reduction in myocardial infarctions (relative risk 0.83; 95% CI, 0.62-1.10); an analogous analysis excluding the Atrial fibrillation Clopidogrel Trial with Irbesartan for the prevention of Vascular Events demonstrated a significant reduction in myocardial infarctions (relative risk 0.80; 95% CI, 0.64-1.00). Warfarin might provide a protective effect against myocardial infarction compared with non-warfarin anticoagulants or “anticoagulation equivalents” in patients with atrial fibrillation who are prescribed anticoagulation for stroke thromboprophylaxis.Does Warfarin for Stroke Thromboprophylaxis Protect Against MI in Atrial Fibrillation Patients? - Corrected ProofGregory Y.H. Lip, Deirdre A. Lane10.1016/j.amjmed.2010.01.031The American Journal of Medicine (2010)2010-07-22The American Journal of Medicine2010-07-22REVIEWhttp://www.amjmed.com/article/PIIS0002934310002317/abstract?rss=yesAbstract: The general medicine and critical care services often care for patients that require therapeutic apheresis. Apheresis procedures are performed for various hematologic, neurological, renal, autoimmune, metabolic, and other indications. To facilitate a prompt start to the procedure, the clinical team must coordinate efforts with several services, including those that perform the apheresis procedure, establish venous access, and provide blood or replacement products, in addition to the pharmacy and clinical laboratory. Some of these tasks are performed typically by the clinical teams, while others are performed typically by the apheresis team. Presented and discussed are the indications for therapeutic apheresis, calculations for the ordering of blood products, and several important and practical details to consider, thus preventing delays in starting the apheresis procedure.Practical Considerations for Planning a Therapeutic Apheresis Procedure - Corrected ProofSuresh G. Shelat10.1016/j.amjmed.2010.01.022The American Journal of Medicine (2010)2010-06-11The American Journal of Medicine2010-06-11REVIEW